Groundbreaking cell therapy trial offers hope for incurable lupus
NCT ID NCT06222853
Summary
This early-stage study is testing the safety and initial effectiveness of a therapy called CAR-T for people with severe, treatment-resistant lupus. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells that drive the disease. The goal is to see if this approach can better control lupus activity and potentially reduce the need for lifelong medications like steroids.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
Conditions
Explore the condition pages connected to this study.